纤维束变化在被认为的LATE和忘记性阿尔茨海默病中如何不同
Aurélie Lebrun1,2, Yann Leprince1, Julien Lagarde2,3,4
1Université Paris-Saclay, UNIACT, NeuroSpin, CEA, Gif-sur-Yvette, France.
概括
阿尔茨海默病 (AD) 和边缘主导的与年龄相关的TDP-43脑病变 (LATE) 在叶和边缘叶表现出类似的白质 (WM) 变化. 此外,LATE还会影响额头连接和大脑-丘脑-皮质管道,使其与AD区分开来.
科学领域:
- 神经成像是一种神经成像.
- 神经退行性疾病 神经退行性疾病
- 神经病理学神经病理学
背景情况:
- 阿尔茨海默病 (AD) 和临主导的与年龄相关的TAR DNA结合蛋白 43 (TDP-43) 脑病变 (LATE) 与类似的记忆障碍症状存在,但在潜在的蛋白质病变中不同.
- 了解这些疾病中明显的神经解剖学变化对于准确的诊断和治疗至关重要.
研究的目的:
- 为了调查白质 (WM) 纤维束变化和早期AD的区域皮质缩,假定LATE和对照.
- 使用先进的扩散MRI技术来区分AD和LATE的神经成像资料.
主要方法:
- 基于Fixel的分析 (FBA) 是一种扩散MRI技术,用于检查WM纤维束的完整性.
- 评估了区域皮层厚度,以补充WM发现.
主要成果:
- 遗忘性AD和假定的LATE都在,边缘和上额头连接道中表现出WM变化.
- 假定LATE显示了连接中额头回旋和大脑 - 脑丘 - 皮层通道的通道中的额外WM变化.
- 在与最显著改变的WM通道相关的区域观察到皮层稀释.
结论:
- 基于Fixel的分析成功地在被认为是LATE患者中识别出明显的WM纤维束变化.
- 观察到的WM退化模式与区域皮质缩和已知的蛋白质病变阶段相一致.
- 基于神经成像的AD和LATE差异化可能会提供对不同蛋白质传播途径的见解.
相关概念视频
01:26Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
03:03Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
01:30Dementia
107
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
107